Growth Metrics

NovoCure (NVCR) Change in Accured Expenses (2016 - 2026)

NovoCure's Change in Accured Expenses history spans 13 years, with the latest figure at -$219000.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 98.67% to -$219000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $27.2 million, a 2459.3% increase, with the full-year FY2025 number at $4.9 million, down 74.1% from a year prior.
  • Change in Accured Expenses hit -$219000.0 in Q1 2026 for NovoCure, down from $513000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for NVCR hit a ceiling of $24.8 million in Q3 2025 and a floor of -$18.2 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $2.4 million across 5 years, with a median of $1000.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: soared 626400.0% in 2023 and later tumbled 1529.02% in 2024.
  • Tracing NVCR's Change in Accured Expenses over 5 years: stood at -$1.4 million in 2022, then soared by 1453.01% to $18.9 million in 2023, then grew by 0.98% to $19.0 million in 2024, then plummeted by 97.31% to $513000.0 in 2025, then plummeted by 142.69% to -$219000.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for NVCR at -$219000.0 in Q1 2026, $513000.0 in Q4 2025, and $24.8 million in Q3 2025.